CPX-351

Name: CPX-351
Brand: TargetMol
SKU: T31088
Price: 1270 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: Vyxeos, CPX351, CPX 351) Copy Product Info

🥰Excellent

Synonyms: Vyxeos, CPX351, CPX 351

Catalog No. T31088 Copy Product Info

Purity: 99.76%

🥰Excellent

CPX-351 (Vyxeos) is a liposomal formulation of cytarabine and daunorubicin with potential antitumor activity. CPX-351 delivers these two compounds to leukemia cells in a synergistic 5:1 ratio, with higher delivery rates than in normal bone marrow cells. CPX-351 is indicated for the treatment of acute myeloid leukemia.

Cas No. 1256639-86-7

Pack Size	Price	USA Stock	Global Stock	Quantity
1 mg	$1,270	In Stock	In Stock
5 mg	$2,550	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.76%

Appearance:Solid

Color:Red

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	CPX-351 (Vyxeos) is a liposomal formulation of cytarabine and daunorubicin with potential antitumor activity. CPX-351 delivers these two compounds to leukemia cells in a synergistic 5:1 ratio, with higher delivery rates than in normal bone marrow cells. CPX-351 is indicated for the treatment of acute myeloid leukemia.
Targets & IC50	NMUR1:45 nM (Kb), NMUR1:7.35 (pA2), Primary AML cells、leukemia blast cells:0.223 µM, Cyt:Daun:0.03:0.006 uM to 10:2 uM
In vitro	Methods: p53 wild-type AML cells (MOLM-13, MV4-11, MOLM-14) were treated with CPX-351 (62.5 nM) alone or in combination with M3814 (500 nM), and apoptosis rates were assessed at various time points using Annexin V flow cytometry. Results: M3814 significantly enhanced CPX-351-induced apoptosis in p53 wild-type AML cells, with a time-dependent increase. [2] Methods: MOLM-13 cells were co-cultured with healthy bone marrow-derived MSCs and treated with CPX-351 alone or in combination with M3814; apoptosis was assessed by Annexin V flow cytometry. Results: MSCs attenuated the apoptosis-inducing effect of CPX-351 monotherapy, whereas the combination of M3814 and CPX-351 significantly reversed the protective effect of MSCs and restored cytotoxicity against AML cells.[2]
In vivo	Methods: C57BL/6 mice (female, 8–10 weeks old) received tail vein injections (CPX-351 group: 12:5.3 mg/kg; “7+3” group: 600:9 mg/kg) every 3 days for a total of 3 doses. Results: The “7+3” group exhibited intestinal injury, colon shortening, inflammatory infiltration, increased permeability, and bacterial translocation. The CPX-351 group showed no such pathological changes, maintaining intestinal barrier integrity and immune function. [1]
Synonyms	Vyxeos, CPX351, CPX 351

Chemical Properties

Molecular Weight	770.74
Formula	C₃₆H₄₂N₄O₁₅
Cas No.	1256639-86-7
Smiles	O[C@@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C(=O)N=C(N)C=C2.OC=1C2=C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@@](C(C)=O)(O)C2)C(O)=C4C1C(=O)C=5C(C4=O)=C(OC)C=CC5
Relative Density.	1.31g/cm3

Storage & Solubility Information

Storage

Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.